KST-6051

Phase 1Small molecule

KKestrel Therapeutics, Inc.

KST-6051 is one of 28 small molecule programs targeting Non-small Cell Lung Cancer (NSCLC). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung Cancer (NSCLC)Recruiting

Non-Small Cell Lung Cancer (NSCLC)Phase 1

Recruiting

Competition

Competitive Landscape

31 competitors in Non-Small Cell Lung Cancer (NSCLC)

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

3 2

Keytruda

Merck & Co.

Phase 3

3 3

DATROWAY

Daiichi Sankyo

Phase 3

1 4

Paraplatin

AAvyxa

Phase 3

3 5

Alimta

GGynecologic Oncology Group

Phase 3

3 6

Taxotere

AAvyxa

Phase 3

2 7

Decadron

AAspen Global Incorporated

Phase 3

1 8

Tylenol

KKenvue Brands

Phase 3

1 9

Pumitamig

Bristol-Myers Squibb

Phase 3

3 10

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT07458347

Clinical

Trials by Indication[1]

Non-small Cell Lung Cancer (NSCLC)1 trial

A First-in-human Phase 1 Dose-escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation

Recruiting·KKestrel Therapeutics, Inc.·Phase 1·NCT07458347·145 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KST-6051. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KST-6051 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KST-6051. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kestrel Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: KKestrel Therapeutics, Inc.

KST-6051

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Non-small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News